NeuCyber NeuroTech acknowledges being 3 years behind Neuralink in BCI development — Reuters confirms China's honest assessment of gap
Summary
Reuters reported that Beijing-backed brain chip firm NeuCyber NeuroTech acknowledged being approximately 3 years behind Neuralink in BCI development, as noted in Neurotech Notables #51 (March 2026). The Reuters report is notable because it represents a rare public self-assessment by a major Chinese BCI company of the technology gap versus the global leader. The disclosure contextualizes the Chinese BCI ecosystem: while Neuracle received the world's first commercial BCI approval (March 2026), and BrainCo raised $286M, and multiple provincial governments have established BCI service pricing, the most advanced Chinese invasive cortical BCI programs remain years behind Neuralink's N1 clinical trial scale and electrode performance.
Why it matters
NeuCyber's honest "3 years behind Neuralink" Reuters admission is more strategically informative than any Chinese BCI press release claiming leadership. It confirms that despite China's extraordinary investment and policy support, the physics and biology of high-channel-count cortical BCI recording remain a genuine technological challenge that money alone cannot compress. The 3-year gap for NeuCyber — given Neuralink's current 21-patient PRIME trial — means Chinese invasive cortical BCI first-in-human clinical trials are likely 2027-2028.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial